Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.
about
Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab.Comparison of the efficiency of ABVD versus BEACOPP for Hodgkin lymphoma treatment: a meta-analysis.Genome-Wide Analysis of 18 Epstein-Barr Viruses Isolated from Primary Nasopharyngeal Carcinoma Biopsy Specimens.Frontline Therapy for Classical Hodgkin Lymphoma by Stage and Prognostic Factors.High frequency of primary refractory disease and low progression-free survival rate of Hodgkin's lymphoma: a decade of experience in a Latin American center.Hodgkin lymphoma: A review and update on recent progress.Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma.First-line escalated BEACOPP does not hinder stem cell collection and transplantation strategy in patients with relapsed/refractory Hodgkin's lymphoma.Transplant strategies in relapsed/refractory Hodgkin lymphoma.Response to the letter by Adams and Kwee, entitled: "Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma".
P2860
Q33442092-8EB32E53-9DE2-4141-9F16-D431E94807EFQ33704061-11A08A64-766A-4DD6-8AF9-DFEAB4E17EAEQ38929198-C5632C16-6CC6-4E47-82AC-2EFA5DEF7220Q40150612-F1529DA9-3931-4D8B-8E84-B83F5C2BAC35Q42287385-951E3C4C-5D0B-409D-90AA-3F2A90A77C2FQ46879226-5B3681B6-3650-4341-B894-35A77E72CA55Q47807176-D394FED5-4FC7-49EA-9C7C-1FAEDEECF48EQ48364403-126D8AF3-C408-4E9D-A702-BC419884934CQ48921913-1D433C5B-205A-4DD0-B08F-CD16B45312CDQ52676516-10B26878-C639-47D5-AEA7-D9C07C97D02DQ52937933-1B945BA4-B4C2-4CED-AF9E-A5344BE07A3D
P2860
Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.
description
2015 nî lūn-bûn
@nan
2015 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Long-Term Results of the HD200 ...... y Fondazione Italiana Linfomi.
@ast
Long-Term Results of the HD200 ...... y Fondazione Italiana Linfomi.
@en
Long-Term Results of the HD200 ...... y Fondazione Italiana Linfomi.
@nl
type
label
Long-Term Results of the HD200 ...... y Fondazione Italiana Linfomi.
@ast
Long-Term Results of the HD200 ...... y Fondazione Italiana Linfomi.
@en
Long-Term Results of the HD200 ...... y Fondazione Italiana Linfomi.
@nl
prefLabel
Long-Term Results of the HD200 ...... y Fondazione Italiana Linfomi.
@ast
Long-Term Results of the HD200 ...... y Fondazione Italiana Linfomi.
@en
Long-Term Results of the HD200 ...... y Fondazione Italiana Linfomi.
@nl
P2093
P50
P356
P1476
Long-Term Results of the HD200 ...... by Fondazione Italiana Linfomi
@en
P2093
Angela Ferrari
Caterina Mammi
Caterina Stelitano
Fiorella Ilariucci
Francesco Angrilli
Giuseppe Polimeno
Luigi Marcheselli
Maurizio Musso
Nicola Cascavilla
Paolo G Gobbi
P304
P356
10.1200/JCO.2015.62.4817
P407
P577
2015-12-28T00:00:00Z